<SEC-DOCUMENT>0001193125-18-296866.txt : 20181010
<SEC-HEADER>0001193125-18-296866.hdr.sgml : 20181010
<ACCEPTANCE-DATETIME>20181010163500
ACCESSION NUMBER:		0001193125-18-296866
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181008
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181010
DATE AS OF CHANGE:		20181010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		181116348

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d635644d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;10, 2018 (October&nbsp;8, 2018) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g635644g92j44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of Incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Woonsocket, Rhode Island</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02895</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (401) <FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the previously announced Agreement and Plan of Merger (the &#147;Merger Agreement&#148;), dated as of December&nbsp;3, 2017, among CVS Health
Corporation (&#147;CVS Health&#148;), Aetna Inc. (&#147;Aetna&#148;) and Hudson Merger Sub Corp., CVS Health and Aetna agreed that, at the completion of CVS Health&#146;s acquisition of Aetna (the &#147;Acquisition&#148;), the size of the board of
directors of CVS Health (the &#147;Board&#148;) would be increased by three and the vacancies created thereby would be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of Aetna, and two other individuals who are serving on the
board of directors of Aetna immediately prior to completion of the Acquisition who meet CVS Health&#146;s independence criteria as in effect as of such time and who would be jointly designated by Aetna and CVS Health prior to completion of the
Acquisition. The Board subsequently decided to add an additional Aetna director to the Board and therefore increase the size of the Board by an additional member, so that a total of four new vacancies will be created and filled upon the completion
of the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, on October&nbsp;8, 2018, the Board approved the increase of the size of the Board from twelve directors to sixteen
directors and appointed Mr. Bertolini, Edward J. Ludwig, Roger N. Farah and Fernando Aguirre (collectively, the &#147;New Directors&#148;) to the Board to fill the resulting vacancies, in each case, effective upon the completion of the Acquisition.
Mr.&nbsp;Bertolini was designated by CVS Health and Aetna in the Merger Agreement and Messrs. Ludwig and Farah were jointly designated by CVS Health and Aetna pursuant to the Merger Agreement and, in each case, in accordance with CVS Health&#146;s
certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> Mr.&nbsp;Aguirre was designated by CVS Health in accordance with its certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Messrs. Ludwig, Farah and Aguirre was determined by the Board to be &#147;independent&#148; under the Corporate Governance Rules of the New York Stock
Exchange and under CVS Health&#146;s Corporate Governance Guidelines. Committee assignments for the New Directors have not yet been determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Directors will be entitled to the same compensation and benefits as CVS Health&#146;s other <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors, which are described in CVS Health&#146;s Proxy Statement filed with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) on April&nbsp;24, 2018. In connection with the Acquisition, the New Directors will receive certain payments
and benefits pursuant to the terms of the Merger Agreement and their existing arrangements with Aetna, which are disclosed in the section of CVS Health&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (No. <FONT
STYLE="white-space:nowrap">333-222412)</FONT> filed with the SEC on January&nbsp;4, 2018, as amended, entitled &#147;<I>Interests of Aetna&#146;s</I><I></I><I>&nbsp;Directors and Executive Officers in the Merger</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no transactions, and there are no currently proposed transactions, in which CVS Health was or is a participant and in which the New Directors
or any of their immediate family members has or will have any interest, that are required to be disclosed under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark T. Bertolini </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bertolini, age 62, has
been a director at Aetna since 2010 and is the Chairman and Chief Executive Officer of Aetna. He assumed the roles of Chairman of Aetna&#146;s board of directors on April&nbsp;8, 2011 and Chief Executive Officer of Aetna on November&nbsp;29, 2010.
From July 2007 to December 2014, he served as President, responsible for all of Aetna&#146;s businesses and operations. Mr.&nbsp;Bertolini joined Aetna in 2003 as head of Aetna&#146;s Specialty Products, and subsequently served as Executive Vice
President and head of Aetna&#146;s regional businesses. Before joining Aetna, Mr.&nbsp;Bertolini held executive positions at Cigna, NYLCare Health Plans, and SelectCare, Inc., where he was President and Chief Executive Officer. Mr.&nbsp;Bertolini
also serves as a director of Verizon Communications, Inc. (communications, information and entertainment products and services), Massachusetts Mutual Life Insurance Company (insurance and investment products and services), the Fidelco Guide Dog
Foundation, the Peterson Institute for International Economics, Thrive Global and the Mind&nbsp;&amp; Life Institute. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Edward J. Ludwig </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ludwig, age 67, is the lead director of Aetna&#146;s board of directors and has been a director at Aetna since 2003. He is the former Chairman of the
board of directors of Becton, Dickinson and Company (&#147;BD&#148;) (global medical technology company), having served in this position from February 2002 through June 2012. He also served as Chief Executive Officer of BD from January 2000 to
September 2011, President of BD from May 1999 to December 2008, and Chief Financial Officer of BD from January 1995 to May 1999. Mr.&nbsp;Ludwig joined BD as a Senior Financial Analyst in 1979. Prior to joining BD, Mr.&nbsp;Ludwig was a senior
auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA, and served as a financial and strategic analyst at Kidde, Inc. Mr.&nbsp;Ludwig also served as Director of Xylem, Inc. (water technology company) from 2011 to
2017, and Chairman of Advanced Medical Technology Association, or AdvaMed, (medical device trade association) from 2006 to 2008. He serves as the lead independent director on the board of directors of Boston Scientific Corporation (medical devices)
and as a director of POCARED Diagnostics Ltd. (diagnostics technology manufacturer). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roger N. Farah </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Farah, age 65, has been a director at Aetna since 2007 and Chairman of the Board and a director of Tiffany&nbsp;&amp; Co. (jewelry and specialty
products). He served as Executive Director of Tory Burch LLC (lifestyle products) from March 2017 to September 2017, having previously served as <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director from September 2014 to
February 2017. He is former Executive Vice Chairman of Ralph Lauren Corporation (lifestyle products) having served in that position from November 2013 to May 2014, and previously served as President and Chief Operating Officer from April 2000 to
October 2013, and Director from April 2000 to August 2014. Earlier, Mr.&nbsp;Farah served as Chairman of the Board of Venator Group, Inc. (now Foot Locker, Inc.) from December 1994 to April 2000, and as its Chief Executive Officer from December 1994
to August 1999. Mr.&nbsp;Farah served as President and Chief Operating Officer of R.H. Macy&nbsp;&amp; Co., Inc. from July 1994 to October 1994. From June 1991 to July 1994, he was Chairman and Chief Executive Officer of Federated Merchandising
Services (retailing), the central buying and product development arm of Federated Department Stores, Inc. (retailing). From 1988 to 1991, Mr.&nbsp;Farah served as Chairman and Chief Executive Officer of Rich&#146;s/Goldsmith&#146;s Department Stores
(retailing) and previously as its President from 1987 to 1988. He held a number of positions of increasing responsibility at Saks Fifth Avenue, Inc. (retailing) from 1975 to 1987. Mr.&nbsp;Farah also serves as a director on the board of directors of
The Progressive Corporation (auto insurance), and Metro Bank PLC (financial services). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fernando Aguirre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Aguirre, age 60, has been a director at Aetna since 2011. Mr.&nbsp;Aguirre served as President and Chief Executive Officer from January 2004 to
October 2012 and Chairman from May 2004 to October 2012 of Chiquita Brands International, Inc. (global distributor of consumer products). Prior to joining Chiquita, Mr.&nbsp;Aguirre worked for more than 23 years in brand management, general
management and turnarounds at The Procter&nbsp;&amp; Gamble Company (&#147;P&amp;G&#148;) (manufacturer and distributor of consumer products). Mr.&nbsp;Aguirre began his P&amp;G career in 1980, serving in various capacities including President and
General Manager of P&amp;G Brazil, President of P&amp;G Mexico, Vice President of P&amp;G&#146;s global snacks and US food products, and President of global feminine care. In July 2002, Mr.&nbsp;Aguirre was named President, special projects,
reporting to P&amp;G&#146;s Chairman and Chief Executive Officer, working on strategy. He served as a director of Coveris (packaging) from 2014 to 2015, Levi Strauss (manufacturer of clothing) from 2010 until August 2014, and Coca-Cola Enterprises
Inc. (manufacturer and distributor of consumer products) from 2005 to 2010. Mr.&nbsp;Aguirre also serves as a director on the board of directors of Barry Callebaut AG (manufacturer of high-quality chocolate and cocoa products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Chief Financial Officer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;10, 2018, CVS Health also announced a transition in the role of Chief Financial Officer following the closing of the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following
the closing of the Acquisition, Eva C. Boratto, age 52, currently CVS Health&#146;s Executive Vice President&nbsp;&#150;&nbsp;Controller and Chief Accounting Officer, will be appointed as Executive Vice President and Chief Financial Officer of CVS
Health effective on the closing date of the Acquisition. She joined CVS Health in 2010 as Senior Vice President, PBM Finance. From 2013 to 2017, Ms.&nbsp;Boratto served as Senior Vice President&nbsp;&#150;&nbsp;Controller and Chief Accounting
Officer. Ms.&nbsp;Boratto has held her current position at CVS Health since March 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced on June&nbsp;6, 2018, David M. Denton, CVS
Health&#146;s current Executive Vice President and Chief Financial Officer, will be leaving CVS Health at the close of the Acquisition. Additionally, CVS Health and Shawn M. Guertin announced on October&nbsp;10, 2018 that, following the closing of
the Acquisition, Mr.&nbsp;Guertin will not serve as Executive Vice President and Chief Financial Officer of CVS Health, but will still continue in his planned employment following the closing of the Acquisition, assisting Ms.&nbsp;Boratto with
integration matters and financial planning strategy through June 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointment to her new position, Ms.&nbsp;Boratto&#146;s annual salary will be
increased to $850,000, and her 2018 target annual cash incentive award will be increased to 150% of her salary. In addition, she will continue to participate in CVS Health&#146;s equity incentive plans, including annual equity incentive awards, and
long-term incentive plan awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A press release related to the matters described in Item 5.02 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> is included in Exhibit
99.1. The information in Exhibit 99.1 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> is being furnished, not filed. Accordingly, the information in Exhibit 99.1 of this Current Report will not be incorporated by reference
into any registration statement filed by CVS Health under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d635644dex991.htm">Press Release issued by CVS Health Corporation on October&nbsp;10, 2018 </A></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of
an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall
there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of
1933, as amended, and otherwise in accordance with applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transaction, CVS Health filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the Securities and SEC,
which includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018 (the &#147;<U>Registration Statement</U>&#148;),
and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and shareholders of Aetna on or about February&nbsp;12, 2018 (the &#147;<U>Joint Proxy Statement/Prospectus</U>&#148;) and the
special meeting of the stockholders of CVS Health and the shareholders of Aetna was held on March&nbsp;13, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER
DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the Registration Statement and the definitive
Joint Proxy Statement/Prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health are available free of charge
within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting
Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;<U>Reform Act</U>&#148;) provides a safe harbor for forward-looking statements made by or on
behalf of CVS Health Corporation (&#147;<U>CVS Health</U>&#148;) or Aetna, Inc. (&#147;<U>Aetna</U>&#148;).&nbsp;&nbsp;&nbsp;&nbsp;This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally
identify forward-looking statements by the use of forward-looking terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148;
&#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only
predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in
this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the closing date of the transactions contemplated by the Agreement and Plan of Merger, dated as of
December&nbsp;3, 2017 (&#147;<U>Merger Agreement</U>&#148;), among CVS Health, Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of CVS Health (the &#147;<U>transaction</U>&#148;), the extent of, and the time necessary to obtain, the
regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the
transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s
expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the
number of prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based
on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information
for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X&nbsp;relating</FONT> to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered
in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those
currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained
subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation
contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition
and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS
Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s
ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s
ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective
filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;as</FONT> updated by their
Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and future filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue
reliance on any CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and
are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished pursuant to Item 7.01 of this Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> shall not be deemed to be &#147;filed&#148; for the purpose of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that
section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The
furnishing of this information is not intended to constitute a determination by CVS Health that the information is material or that the dissemination of the information is required by Regulation FD. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CVS HEALTH CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Corporate Secretary and Assistant General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:65%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dated: October&nbsp;10, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d635644dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g635644g92j44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Provides Update to Board and Management Roles </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Upon Closing of Aetna Acquisition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Will expand Board to include three additional Aetna Directors with deep insurance company oversight experience </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Eva Boratto to become CFO; Shawn Guertin to remain with company for transition period to play key role in financial integration </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Woonsocket, RI (October 10, 2018) </B>&#150; CVS Health (NYSE: CVS) today announced that three additional Aetna directors with deep insurance company
oversight experience &#151; Edward J. Ludwig, Fernando Aguirre, and Roger N. Farah &#151; will join the CVS Health Board following the completion of its acquisition of Aetna. The appointment of these three Aetna directors, together with the
previously announced addition of Mark T. Bertolini, Aetna&#146;s current Chairman and Chief Executive Officer, will bring the total number of CVS Health Board members to 16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health also announced today that following the completion of the transaction, Eva C. Boratto, currently CVS Health&#146;s Executive Vice
President&nbsp;&#150;&nbsp;Controller and Chief Accounting Officer, will become Executive Vice President and Chief Financial Officer of CVS Health. Shawn M. Guertin has decided to step away for personal and family reasons, but will remain with CVS
Health until June 2019 to help the combined company with integration and financial planning strategy. As previously disclosed, Aetna will be managed as a distinct operating entity within the CVS Health organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While this was a highly personal decision for Shawn, he is reassured with the knowledge that the company has an extremely strong finance team. During <FONT
STYLE="white-space:nowrap">pre-close</FONT> integration work, Shawn came to value the depth and breadth of talent in the CVS Health finance organization that will be complemented by the deep and talented bench in the Aetna finance group,&#148; said
Larry J. Merlo, President and Chief Executive Officer. &#147;We respect Shawn and wish him well.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Expansion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to welcome Fernando, Mark, Roger and Ed to the CVS Health Board,&#148; said David W. Dorman, Chairman of CVS Health. &#147;Our
shareholders will benefit from the depth of their knowledge of Aetna&#146;s business and their complementary expertise, which will be essential to the combined company as we transform the way health care is delivered in America.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ludwig joined the Aetna Board of Directors in 2003 and has served as Lead Director since 2012. He also is a member of the executive, investment and
finance, nominating and corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governance, and compensation and talent management committees. Mr.&nbsp;Farah joined the Aetna Board in 2007 and chairs the compensation and talent management committee, and he is a member of the
executive and investment and finance committees. Mr.&nbsp;Aguirre joined the Aetna Board in 2011 and chairs the nominating and corporate governance committee, and he is a member of the executive and audit committees. The terms of Messrs. Aguirre,
Bertolini, Farah and Ludwig on the CVS Health Board will begin immediately after the closing of the Aetna acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CFO Appointment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eva Boratto has an extensive financial background that spans more than 20 years and includes senior positions in both the pharmaceutical manufacturing and PBM
industries, along with other health care finance roles. She joined CVS Health in 2010 as Senior Vice President, PBM Finance and most recently has served as CVS Health&#146;s Executive Vice President&nbsp;&#150;&nbsp;Controller and Chief Accounting
Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining CVS Health, Ms. Boratto served in a number of executive positions at Merck&nbsp;&amp; Co., including Vice President, U.S.
Market Finance Leader, with responsibility for financial oversight of Merck&#146;s U.S. pharmaceutical market, and Vice President, Investor Relations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Eva is an exceptionally talented leader with broad financial experience and excellent management capabilities who, during her nearly ten years at CVS
Health, has served as a trusted advisor to me and to our Board of Directors,&#148; Merlo said. &#147;With knowledge of our business and of all aspects of the financial function of a multi-faceted organization, she will play a vital role in both our
integration work and in our efforts to drive needed change in our health care system to deliver both near and long-term value for our shareholders.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW BOARD MEMBER BIOS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr.</B><B></B><B>&nbsp;Ludwig</B> has served on the Aetna Board since 2003 and has served as Aetna&#146;s Lead Director since 2012. He has significant
executive-level leadership and business expertise with more than 30 years of experience in the medical technology field, including serving for over ten years in each of the roles of Chief Executive Officer and Chairman of Becton, Dickinson and
Company after serving as its Chief Financial Officer. He also has significant public company board experience serving on the board of several companies, including Boston Scientific Corporation, where he is currently the Lead Independent Director.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr.</B><B></B><B>&nbsp;Aguirre</B> has served on the Aetna Board since 2011 and has extensive consumer products, global business and executive
leadership experience, including as Chief Executive Officer and Chairman of Chiquita Brands International, Inc. from 2004 to 2012 and in several senior positions over 23 years at The Procter&nbsp;&amp; Gamble Company. He also has served as an
independent director on several other public company boards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr.</B><B></B><B>&nbsp;Farah</B> has served on the Aetna Board since 2007 and has
extensive business and leadership experience. He has developed strong marketing, brand management and consumer insights in his over 40 years in the retail industry, including as <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer,
Director and Executive Director of Tory Burch LLC and President, Chief Operating Officer, Director and Vice Chairman of Ralph Lauren Corporation. He also has extensive experience serving on a number of public company boards and is currently the
Chairman of the Board of Tiffany&nbsp;&amp; Co. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CVS Health</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,800 retail locations, more than 1,100 <FONT
STYLE="white-space:nowrap">walk-in</FONT> medical clinics, a leading pharmacy benefits manager with approximately 94&nbsp;million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding
specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases
access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at&nbsp;<U>https://www.cvshealth.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike McGuire </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(401) <FONT STYLE="white-space:nowrap">770-4050</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>michael.mcguire@cvshealth.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carolyn Castel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Carolyn.Castel@CVSHealth.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">401-770-5717</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for
informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the transaction, CVS Health filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the Securities and SEC, which includes a joint proxy statement of CVS Health and Aetna that also constitutes a
prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018 (the &#147;Registration Statement&#148;), and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to
stockholders of CVS Health and shareholders of Aetna on or about February&nbsp;12, 2018 (the &#147;Joint Proxy Statement/Prospectus&#148;) and the special meeting of the stockholders of CVS Health and the shareholders of Aetna was held on
March&nbsp;13, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY
CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the Registration Statement and the definitive Joint Proxy Statement/Prospectus and other documents filed with the SEC by CVS Health or Aetna
through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health are available free of charge within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors
or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on
Aetna&#146;s internet website at http://www.Aetna.com or by contacting Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for forward-looking statements made by or on behalf of
CVS Health Corporation (&#147;CVS Health&#148;) or Aetna, Inc. (&#147;Aetna&#148;). This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of
forward-looking terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148;
&#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148;
&#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties,
many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are
forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the closing date of the transactions contemplated by the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017 (&#147;Merger Agreement&#148;), among CVS
Health, Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of CVS Health (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the
transaction, the impact of the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health
stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio following the closing
of the transaction, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies&#146; pharmacy
benefit business, the synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and
projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates,
assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the required pro forma
adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to
the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory
approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the
outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and attention of
management of both CVS Health and Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking statements regarding
CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or
Aetna or that they currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS
Health&#146;s ability to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse
effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and
assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on any CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and
will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise
forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g635644g92j44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g635644g92j44.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0@A\J*3^ 8'#'Z5G&LTCJJY0ZF)]HW[K-/P[_;WC3PAK(U9_-BECV6P,>W+
M9S^8%6I.46<N(5#!XB"AT>IY?IT-QJEW8:.K$[Y]JIZ%L!OT KFA>Y]+6J4X
M4W7\CU7X@ZQ_82V6FW&BPW>GM" CN/NL."/8XQ^==4SYK+J;Q$Y5(RM*YYOK
M[^'IA ^A0SQEQ^]B<Y4>@'?K7/).^A]!AUB$G[9Z'<^(9E@T'X=6NK31^<NI
MV[RI,1G9M<9(/;M7=2VU/A\:X_6)<IV7C:TT:V\!ZY/]FM(@]A,(Y-BC+&-M
MN#ZU9R'FUP\IB^&^H6^K+I]LFF_93=JH=8IC&GRGT)QB@#=U32)[G6M"L]6\
M:_;9!>QSV\$,"EMZGJ2.0,'K0!I_#J^L],NO$>CW\B6VJ)J<UPXE8 R1NWR,
M">HQQ^% %'PMK&EZI\:?$\NGR1F-K**,.",3,O4CU]/PH Y8SQ-^S[<Q"13)
M!J1,J#&Z,&Z[CM0!V_CK4-/D\5>!7^UP-&-0:0L'&W&P\_G0!)\2[JV@O_!9
M>:-"-=@D.2!\NU\GZ=* /0A(I4,&!!&01WH =0!6O;"VU"U:VNX5EA;JK#(-
M%D73J2IN\2:.%(HUCC4*BC  Z 4+03DY.["2%)8VCD4,C#!!&012L)2<7=;F
M"W@?PX]R)SI4&_.?N\'\*GV<>QVK,,0H\O,;D4$=O$L4"+'&O 51@"JBE%6.
M*<I3=V]3/@\-Z/:WBW<&GP1SJ<APO(/K1RQ['1+%5I4_9N6A:O=-M=1@,%Y
MDT1_A<9I2BF9TJLZ+O!V9EVG@OP]8SB:WTN!) <@[<XJ532.B>88F:LY%C4O
M#&BZQ<)/J.G0W,J*$5G7) !S@?C6FQQ>98O=%TW4=/2PO+..:T3&V)AP,=*
M((_#.BQ:5)I:Z;;BQD;>T&S*EO7% $>C^$M"T&9IM,TZ*"5O^6@&6'T)Z4 &
ML>$M"UZ5)=2TV*>5. ^,-@=LCM0!+;^&M&L[V&\M]-MX;B!/+C=$ *KZ#\Z
M&IX7T.,7JKIEN$OL?:$V<28]1]: *[^"?#<D<,<FD6[K NV/<N=HSV_.@"UJ
M7AO1]7>-]0T^&X:)=J%U^Z/04 :4<20Q)%&-B( %4= * 'T % !0 4 % !0
94 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
